You are here: Welcome » Kyla Hildebrand

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
kyla_hildebrand [2022/04/18 20:31]
liam [Funding]
kyla_hildebrand [2022/04/18 22:26] (current)
liam [Funding]
Line 22: Line 22:
  
 Hildebrand has received funding from [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:CSL Behring]], [[pharmaceutical_companies:MEDA Pharmaceuticals]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Shire Pharma]], [[pharmaceutical_companies:Stallergenes Greer]], [[pharmaceutical_companies:Takeda]], [[pharmaceutical_companies:Teva]], [[pharmaceutical_companies:Aralez]] and Hildebrand has received funding from [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:CSL Behring]], [[pharmaceutical_companies:MEDA Pharmaceuticals]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Shire Pharma]], [[pharmaceutical_companies:Stallergenes Greer]], [[pharmaceutical_companies:Takeda]], [[pharmaceutical_companies:Teva]], [[pharmaceutical_companies:Aralez]] and
-[[pharmaceutical_companies:Pediapharm]].((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1))+[[pharmaceutical_companies:Pediapharm]] as recently as 2018.((Quirt, J., Hildebrand, K. J., Mazza, J., Noya, F., & Kim, H. (2018). //Asthma.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0279-0)) ((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) She has also received speakers fees from [[pharmaceutical_companies:Novartis]], and paid travel expenses for [[AllerGen]].((Soller, L., Abrams, E. M., Carr, S., Kapur, S., Rex, G. A., Leo, S., Lidman, P. G., Yeung, J., Vander Leek, T. K., McHenry, M., Wong, T., Cook, V. E., Hildebrand, K. J., Gerstner, T. V., Mak, R., Lee, N. J., Cameron, S. B., & Chan, E. S. (2019). //First real-world safety analysis of preschool peanut oral immunotherapy.// The Journal of Allergy and Clinical Immunology: In Practice, 7(8), 2759-2767.e5. https://doi.org/10.1016/j.jaip.2019.04.010))
  
-She has also served as a consultant for [[Food Allergy Canada]], and has received honoraria from [[Health Canada]]. She received a research grant from the [[Canadian Allergy, Asthma, and Immunology Foundation]].+She has also served as a consultant for [[Food Allergy Canada]], and has received honoraria from [[Health Canada]]. She received a research grant from the [[Canadian Allergy, Asthma, and Immunology Foundation]].((Waserman, S., Cruickshank, H., Hildebrand, K. J., Mack, D., Bantock, L., Bingemann, T., Chu, D. K., Cuello-Garcia, C., Ebisawa, M., Fahmy, D., Fleischer, D. M., Galloway, L., Gartrell, G., Greenhawt, M., Hamilton, N., Hourihane, J., Langlois, M., Loh, R., Muraro, A., & Rosenfield, L. (2021). //Prevention and management of allergic reactions to food in child care centers and schools: Practice guidelines.// Journal of Allergy and Clinical Immunology, 147(5), 1561–1578. https://doi.org/10.1016/j.jaci.2021.01.034)) 
 + 
 +[[Food Allergy Canada]] is partnered with [[pharmaceutical_companies:Pfizer]].((//Who we work with.// Food Allergy Canada. Retrieved April 18, 2022, from https://archive.ph/e2uhY)) 
 + 
 +She has received further funding from [[Genome British Columbia]] and the [[BC Children's Hospital Foundation]].((Blanchard-Rohner, G., Ragotte, R. J., Junker, A. K., Sharma, M., Del Bel, K. L., Lu, H. Y., Erdle, S., Chomyn, A., Gill, H., Tucker, L. B., Schreiber, R. A., Rozmus, J., Biggs, C. M., Hildebrand, K. J., Wu, J., Stockler-Ipsiroglu, S., & Turvey, S. E. (2021). //Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report.// BMC Pediatrics, 21(1). https://doi.org/10.1186/s12887-021-02508-3)) ((Roberts, H., Soller, L., Ng, K., Chan, E. S., Roberts, A., Kang, K., Hildebrand, K. J., & Wong, T. (2020). //First pediatric electronic algorithm to stratify risk of penicillin allergy.// Allergy, Asthma & Clinical Immunology, 16(1). https://doi.org/10.1186/s13223-020-00501-6)) She has published NACI papers with funding from the [[Public Health Agency of Canada]].((Dayneka, N., Jensen, C., & Hildebrand, K. (2020). //Canadian Immunization Guide: “Anaphylaxis and other acute reactions following vaccination” chapter update.// Canada Communicable Disease Report, 46(1112), 384–386. https://doi.org/10.14745/ccdr.v46i1112a04))
Back to top